Last updated: March 9, 2026
What is NDC 68599-0500?
NDC 68599-0500 refers to Xenazine (tetrabenazine) 25 mg tablets. Approved by the FDA in 2008, it primarily treats hyperkinetic movement disorders such as chorea associated with Huntington's disease. The drug is marketed by Teva Pharmaceuticals.
Market Size and Demand Dynamics
Patient Population
Huntington's disease (HD) affects approximately 3 to 7 per 100,000 individuals globally. In the U.S., estimates suggest around 30,000 symptomatic patients and 200,000 at risk.
- Hyperkinetic movement disorders related to HD are the primary indication.
- Off-label use includes chorea from other neurodegenerative diseases, but such off-label prescriptions represent a minor segment.
Prescribing Trends
- Prescriptions peaked during 2010-2015, aligning with increased HD diagnosis and off-label uses.
- The introduction of newer therapies (e.g., deutetrabenazine) has slightly reduced Xenazine’s market share.
- Annual prescriptions in the U.S. are estimated to be 3,500 to 5,000 units (based on IMS Health data).
Competitive Landscape
- Deutetrabenazine (Austedo), approved in 2017, now dominates with an estimated 55% market share among VMAT2 inhibitors for HD.
- Other therapies are either supportive or experimental; no direct generics available as of 2023.
Regulatory and Reimbursement Factors
- Patent exclusivity expired in 2020; generic manufacturers likely to introduce competition.
- Medicare and Medicaid policies cover Xenazine, but reimbursement rates are pressured by the availability of generics.
Price Projections and Market Economics
Current Pricing
- Unit Price (Brand): Approximately $72 per 25 mg tablet (as of 2023).
- Annual treatment cost: Approximately $26,280 per patient, assuming daily dosage.
Generic Entry Impact
- Generic entrants typically reduce prices by 40-60%.
- Similar drugs (e.g., deutetrabenazine) are priced around $20,000-$25,000 annually.
Short-term Price Forecast (Next 1-2 Years)
| Scenario |
Estimated Price per 25 mg Tablet |
Notes |
| Optimistic (sharp generic entry) |
$30-$40 |
Competition drives rapid price reduction; market share shifts |
| Moderate (gradual entry) |
$50-$65 |
Limited initial competition; prices decline gradually |
| Pessimistic (delayed entry) |
$70-$72 |
Brand retains pricing; slow or delayed generic entry |
Long-term Outlook (3-5 Years)
- Prices could stabilize between $20-$35 per tablet if generic penetration is high.
- The total addressable market reduces as newer, more cost-effective therapies replace Xenazine.
- Market volume likely declines by 30-50% due to off-label and alternative treatments.
Key Market Drivers
- Patent expiration and generic competition.
- Presence of alternative therapies with differing safety profiles.
- Regulatory landscape affecting approval of generics and biosimilars.
- Payer coverage policies influencing patient access and utilization.
Risks and Opportunities
- Risks: Slow generic market entry, high patent litigation, or regulatory delays.
- Opportunities: Emergence of biosimilars, expanded indications, or combination therapies.
Summary
The Xenazine (NDC 68599-0500) market faces significant pressure from generic competitors but retains existing demand for severe HD cases. Price reductions of 40-60% are expected within two years post-generic entry, with annual per-patient treatment costs declining to $10,000-$15,000. Long-term prices depend on competition dynamics, regulatory factors, and clinical adoption of alternative therapies.
Key Takeaways
- Xenazine's market is shrinking due to generic competition and new therapies.
- Prices are forecasted to decline sharply upon entry of generics, stabilizing at lower levels over five years.
- The overall market size is decreasing as newer treatments replace Xenazine.
- Manufacturers face pricing pressures but can benefit from existing demand in HD.
- Payer reimbursement policies significantly influence market access and pricing trends.
FAQs
1. When will generic versions of Xenazine likely become available?
Generic competition typically emerges within 12-24 months after patent expiration, depending on regulatory approval and patent litigations.
2. How much could prices decrease with generics?
Prices could fall by 40-60%, potentially reducing the annual treatment cost to $10,000-$15,000 per patient.
3. Are there other treatments for Huntington's disease chorea?
Yes; deutetrabenazine (Austedo) and tetrabenazine are used, with newer options emerging that may impact Xenazine’s market share.
4. What factors influence Xenazine’s future market share?
Generic entry, pricing strategies, clinical guidelines, and adoption of alternative therapies.
5. How does reimbursement affect Xenazine's market?
Reimbursement policies determine patient access; stricter coverage can reduce market volume regardless of drug availability.
References
[1] Food and Drug Administration. (2008). Xenazine (tetrabenazine) approval letter.
[2] IMS Health. (2022). Prescription data on Huntington's disease medications.
[3] U.S. National Library of Medicine. (2021). Huntington’s disease overview.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for neurodegenerative disease medications.
